Baxa to Feature ValiMed™ Medication Validation System at Interphex 2006
Baxa Corporation features the innovative ValiMed System technology for rapid validation of high-risk medications at the Interphex 2006 trade show March 20-23, 2006, at Booth # C302. This new system provides the only effective means for preventing med errors, detecting narcotic abuse and ensuring the quality of batch compounds.
Denver, CO, March 20, 2006 --(PR.com)-- Baxa Corporation will feature its new ValiMed Medication Validation System at the upcoming Interphex meeting at the Jacob Javits Convention Center in New York City (http://interphex.com). Over the course of the three-day meeting, Baxa representatives will demonstrate how this unique technology prevents medication errors by validating drugs and concentrations, detecting counterfeit products for brand protection, and providing quality assurance for compounded products. The ValiMed System also is used for prevention and detection of narcotic diversion.
The ValiMed System provides clinicians a simple, cost-effective tool for ensuring medication safety. Its patent-pending technology identifies drug strength in real time, validating compounded doses of high-risk medications prior to dispensing. “The ValiMed Solution fits with Baxa Corporation's mission to improve pharmacy operations and increase the safety of admixture and administration activities,” notes Product Manager Mark Thrasher. “ValiMed complements our existing automation, admixture and drug delivery products well.”
According to the National Institute on Drug Abuse (NIDA), between 8% and 12% of healthcare workers have chemical dependencies. Healthcare professionals may be at increased risk of prescription drug abuse because of their easy access to medications, including controlled substances. Using the ValiMed Technology, pharmacy directors and other managers can detect narcotic loss and prevent on-the-job impairment, which can compromise patient care.
Pharmacists and other healthcare professionals continue to explore new uses for the medication validation offered by the ValiMed System. The system has applications for clinical trial validation and quality control, as well. The future of healthcare safety will be demonstrated at booth no. C302 during the Interphex exhibit hours.
For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency. Under an agreement announced in early November, Baxa is the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; sales infrastructure in Belgium, Denmark, Finland, France, Germany, Luxembourg and the Netherlands; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTCBB: CEXI), is a technology development company focused on products using chemical detection and validation technologies. CDEX technology currently covers two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www.cdex-inc.com.
###
Additional information about the new ValiMed™ Medication Validation System and medication errors may be found at http://publicrelationsnewsroom.com/_wsn/page15.html.
Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation http://www.baxa.com: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations http://www.absolutelypr.com: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
The ValiMed System provides clinicians a simple, cost-effective tool for ensuring medication safety. Its patent-pending technology identifies drug strength in real time, validating compounded doses of high-risk medications prior to dispensing. “The ValiMed Solution fits with Baxa Corporation's mission to improve pharmacy operations and increase the safety of admixture and administration activities,” notes Product Manager Mark Thrasher. “ValiMed complements our existing automation, admixture and drug delivery products well.”
According to the National Institute on Drug Abuse (NIDA), between 8% and 12% of healthcare workers have chemical dependencies. Healthcare professionals may be at increased risk of prescription drug abuse because of their easy access to medications, including controlled substances. Using the ValiMed Technology, pharmacy directors and other managers can detect narcotic loss and prevent on-the-job impairment, which can compromise patient care.
Pharmacists and other healthcare professionals continue to explore new uses for the medication validation offered by the ValiMed System. The system has applications for clinical trial validation and quality control, as well. The future of healthcare safety will be demonstrated at booth no. C302 during the Interphex exhibit hours.
For more than 30 years, Baxa Corporation has focused on developing systems and devices that streamline pharmacy operations, enhancing patient safety and improving efficiency. Under an agreement announced in early November, Baxa is the exclusive distributor of the CDEX ValiMed System for healthcare organizations in the United States and Canada.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; sales infrastructure in Belgium, Denmark, Finland, France, Germany, Luxembourg and the Netherlands; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc.
CDEX Inc. (OTCBB: CEXI), is a technology development company focused on products using chemical detection and validation technologies. CDEX technology currently covers two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance. CDEX is headquartered in Rockville, Maryland, with a primary research and development laboratory in Tucson, Arizona. For more information, visit http://www.cdex-inc.com.
###
Additional information about the new ValiMed™ Medication Validation System and medication errors may be found at http://publicrelationsnewsroom.com/_wsn/page15.html.
Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation http://www.baxa.com: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations http://www.absolutelypr.com: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
Contact
Baxa Corporation
Maggie Chamberlin Holben, APR
303.984.9801 or 303.669.3558
http://www.baxa.com
Maggie Chamberlin Holben, APR
303.984.9801 or 303.669.3558
http://www.baxa.com
Contact
Categories